Showing results (271-280 of 329) with videos related to
Sort By:
Pageof 33
Circulation|May 22, 2002
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluationChristopher K Dyke, Richard C Becker, Neal S Kleiman, et al.The New England Journal of Medicine|September 1, 2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromesLars Wallentin, Richard C Becker, Andrzej Budaj, et al.Circulation|February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.European Heart Journal. Quality of Care & Clinical Outcomes|September 17, 2018
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.Heart (British Cardiac Society)|February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.Hypertension (Dallas, Tex. : 1979)|May 5, 2020
Subclinical Systolic and Diastolic Dysfunction Is Evident in Youth With Elevated Blood PressureAndrew H Tran, Joseph T Flynn, Richard C Becker, et al.Journal of the American Heart Association|April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trialJonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.JACC. Cardiovascular Interventions|August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF TrialMatthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.American Heart Journal|September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.Hypertension (Dallas, Tex. : 1979)|September 18, 2024
Systolic Blood Pressure, Cardiovascular Health, and Neurocognition in AdolescentsStephen R Hooper, Marc B Lande, Joseph T Flynn, et al.Pageof 33